Novelrad — Israeli Startup

About

The device deploys a multipoint purse string suture at the beginning of the procedure, thereby, enabling safe dilation and reliable closure at the end of the procedure.

The Novelrad VCD features an unprecedented range of bore sizes using a single device.

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Novelrad's primary focus in the medical device sector?

Novelrad specializes in developing a minimally-invasive suturing device for vascular and heart defect closure, utilizing a micro sewing machine to deploy continuous suture patterns percutaneously.

When was Novelrad founded?

Novelrad was founded in January 2019.

Where is Novelrad's headquarters located?

Novelrad's headquarters is located in Metzer, Israel.

How many employees does Novelrad currently have?

Novelrad currently has between 1 and 10 employees.

Has Novelrad received any grants?

In February 2024, Novelrad received a grant from the IIA (Israel Innovation Authority).

What is Novelrad's current funding stage?

Novelrad is currently in the Pre-Funding stage.

Who are the founders of Novelrad?

The founders of Novelrad are Netanel Sharabani and Ori Goldor.

What is the core technology behind Novelrad's device?

Novelrad's core technology is a micro sewing machine that can deploy a range of continuous suture patterns percutaneously, designed to mimic the surgical 'gold standard' for various cardiovascular indications.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics

Target customers

Healthcare & Life SciencesHealthcareProviders

Business model

B2B

Novelrad — Full Company Profile (machine-readable)

Minimally-invasive Suturing for Vascular and Heart Defect Closure

About

Novelrad has developed a micro sewing machine that can deploy a range of continuous suture patterns, percutaneously, with a simple click of a button. The versatile suturing platform mimics the surgical ‘gold standard’ and can address multiple indications in the cardiovascular system and beyond. The device deploys a multipoint purse string suture at the beginning of the procedure, thereby, enabling safe dilation and reliable closure at the end of the procedure. The Novelrad VCD features an unprecedented range of bore sizes using a single device.

Facts

Name	Novelrad
Slug	novelrad
Type	Israeli Startup
Founded	2019
HQ city	Metzer
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object]
Status	active
Current stage	Pre-Funding
Public stage	Pre-Funding
Total raised (USD)	0
Website	https://novelrad.com/
Israeli Companies Registrar	515962033

Team (2)

Name	Role	LinkedIn
Netanel Sharabani
Ori Goldor

News mentions (1)

Feb 29, 2024 — rasph.com: Article

Intelligence Q&A

What is Novelrad's primary focus in the medical device sector?

Novelrad specializes in developing a minimally-invasive suturing device for vascular and heart defect closure, utilizing a micro sewing machine to deploy continuous suture patterns percutaneously.

When was Novelrad founded?

Novelrad was founded in January 2019.

Where is Novelrad's headquarters located?

Novelrad's headquarters is located in Metzer, Israel.

How many employees does Novelrad currently have?

Novelrad currently has between 1 and 10 employees.

Has Novelrad received any grants?

In February 2024, Novelrad received a grant from the IIA (Israel Innovation Authority).

About

Company Intelligence Q&A

Sectors & technology

Tags

Generate Slim Page